Literature DB >> 22025115

Residual renal function is an independent determinant of serum FGF-23 levels in dialysis patients.

Liesbeth Viaene1, Bert Bammens, Björn K I Meijers, Yves Vanrenterghem, Dirk Vanderschueren, Pieter Evenepoel.   

Abstract

BACKGROUND: Both poor residual renal function (RRF) and high fibroblast growth factor 23 (FGF-23) levels are associated with arterial stiffness, left ventricular hypertrophy and increased (cardiovascular) mortality. Whether FGF-23 and RRF are interrelated is unknown.
METHODS: We performed a prospective observational cohort study in 35 peritoneal dialysis (PD) patients with evaluation at 1, 6, 12 and 24 months after start of PD. In addition, the role of RRF was assessed in a cross-sectional observational cohort study including 68 prevalent haemodialysis patients.
RESULTS: RRF significantly declined over time in PD patients. This decline was parallelled by a significant increase of both serum phosphorus and FGF-23 levels. In the prevalent dialysis cohort, RRF was found to be inversely associated with serum FGF-23 levels, independent of dialysis vintage, dialytic creatinine clearance, estimates of dietary phosphate intake (i.e. normalized protein nitrogen appearance), active vitamin D therapy and serum phosphorus and calcium levels. RRF, serum phosphorus and calcium levels and active vitamin D therapy explain 69% of the variation in FGF-23. The 38 anuric patients had higher FGF-23 levels but similar serum phosphorus levels.
CONCLUSIONS: We demonstrate an important association between RRF and FGF-23, independent of classical determinants. This favours the hypothesis that the ailing kidney directly contributes to the raised FGF-23 levels. Whether FGF-23 is associated with poor outcomes independent of RRF, or vice versa, remains to be clarified.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22025115     DOI: 10.1093/ndt/gfr596

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  17 in total

1.  Associations of fibroblast growth factor 23 with parameters of phosphate metabolism in incident peritoneal dialysis patients.

Authors:  Edyta Golembiewska; Krzysztof Safranow; Joanna Kabat-Koperska; Kazimierz Ciechanowski; Joanna Bober; Anna Bogacka
Journal:  Perit Dial Int       Date:  2013 Jul-Aug       Impact factor: 1.756

2.  Single Measurements of Carboxy-Terminal Fibroblast Growth Factor 23 and Clinical Risk Prediction of Adverse Outcomes in CKD.

Authors:  Daniel Edmonston; Daniel Wojdyla; Rupal Mehta; Xuan Cai; Claudia Lora; Debbie Cohen; Raymond R Townsend; Jiang He; Alan S Go; John Kusek; Matthew R Weir; Tamara Isakova; Michael Pencina; Myles Wolf
Journal:  Am J Kidney Dis       Date:  2019-08-21       Impact factor: 8.860

3.  Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells.

Authors:  Beatrice Richter; Jacqueline Haller; Dieter Haffner; Maren Leifheit-Nestler
Journal:  Pflugers Arch       Date:  2016-07-22       Impact factor: 3.657

4.  FGF-23 and cognitive performance in hemodialysis patients.

Authors:  David A Drew; Hocine Tighiouart; Tammy M Scott; Kristina V Lou; Li Fan; Kamran Shaffi; Daniel E Weiner; Mark J Sarnak
Journal:  Hemodial Int       Date:  2013-10-24       Impact factor: 1.812

5.  Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function.

Authors:  Mengjing Wang; Li You; Haiming Li; Yong Lin; Zhijie Zhang; Chuanming Hao; Jing Chen
Journal:  Clin J Am Soc Nephrol       Date:  2012-10-18       Impact factor: 8.237

Review 6.  FGF23 at the crossroads of phosphate, iron economy and erythropoiesis.

Authors:  Daniel Edmonston; Myles Wolf
Journal:  Nat Rev Nephrol       Date:  2019-09-13       Impact factor: 28.314

Review 7.  Update on fibroblast growth factor 23 in chronic kidney disease.

Authors:  Myles Wolf
Journal:  Kidney Int       Date:  2012-05-23       Impact factor: 10.612

8.  Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis.

Authors:  Kullaya Takkavatakarn; Thunyatorn Wuttiputhanun; Jeerath Phannajit; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Paweena Susantitaphong
Journal:  Int Urol Nephrol       Date:  2021-04-02       Impact factor: 2.370

9.  Sonographic measurement of renal size in patients undergoing chronic hemodialysis: Correlation with residual renal function.

Authors:  Wu-Xing Zhang; Zhi-Min Zhang; Bing-Sheng Cao; Wei Zhou
Journal:  Exp Ther Med       Date:  2014-02-19       Impact factor: 2.447

10.  Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients?

Authors:  Sunny Eloot; Wim Van Biesen; Griet Glorieux; Nathalie Neirynck; Annemieke Dhondt; Raymond Vanholder
Journal:  PLoS One       Date:  2013-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.